ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HCM.GB HUTCHMED China Limited

290.00
-10.00 (-3.33%)
26 Apr 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
HUTCHMED China Limited AQSE:HCM.GB Aquis Stock Exchange Ordinary Share KYG4672N1198
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -3.33% 290.00 280.00 300.00 310.00 287.00 310.00 3,884 16:29:52
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Hutchmed (China) Limited Annual General Meeting Poll Results (2881Z)

12/05/2023 1:15pm

UK Regulatory


HUTCHMED China (AQSE:HCM.GB)
Historical Stock Chart


From Apr 2023 to Apr 2024

Click Here for more HUTCHMED China Charts.

TIDMHCM

RNS Number : 2881Z

Hutchmed (China) Limited

12 May 2023

Annual General Meeting held on May 12, 2023 !V Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 12, 2023: HUTCHMED (China) Limited (" HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM..) held on May 12, 2023 were duly passed. The poll results of the resolutions were as follows:

 
                                                               Number of Votes (%)* 
                                                                                                     Passed 
 Ordinary Resolutions                                     For        Against      Withheld(#)    by Shareholders 
                                                    ------------  -----------  -------------- 
         To consider and adopt the audited 
          financial statements, and the 
          reports of the directors and independent 
          auditors for the year ended December 
 1.       31, 2022.                                  571,825,129      768        17,055,535           Yes 
                                                      (99.9999%)    (0.0001%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Mr TO Chi Keung, Simon 
 2(A).    as a director.                             561,123,049   24,976,533     2,781,850           Yes 
                                                      (95.7385%)    (4.2615%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Dr Weiguo SU as a 
 2(B).    director.                                  587,563,585   1,275,082       42,765             Yes 
                                                      (99.7835%)    (0.2165%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Mr CHENG Chig Fung,                           2,037,527 
 2(C).    Johnny as a director.                      586,799,765    (0.3460%)      44,140             Yes 
                                                      (99.6540%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Dr Dan ELDAR as a 
 2(D).    director.                                  585,955,689   2,882,978       42,765             Yes 
                                                      (99.5104%)    (0.4896%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Ms Edith SHIH as a 
 2(E).    director.                                  585,511,051   3,327,616       42,765             Yes 
                                                      (99.4349%)    (0.5651%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Mr Lefei SUN as a 
 2(F).    director.                                  585,955,594   2,883,073       42,765             Yes 
                                                      (99.5104%)    (0.4896%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Mr Paul Rutherford 
 2(G).    CARTER as a director.                      588,835,909     1,383         44,140             Yes 
                                                      (99.9998%)    (0.0002%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Mr Graeme Allan JACK 
 2(H).    as a director.                             582,880,781   3,218,176      2,782,475           Yes 
                                                      (99.4509%)    (0.5491%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-elect Professor MOK Shu 
 2(I).    Kam, Tony as a director.                   575,206,823   13,631,844      42,765             Yes 
                                                      (97.6850%)    (2.3150%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
         To re-appoint PricewaterhouseCoopers 
          and PricewaterhouseCoopers Zhong 
          Tian LLP as the auditors of the 
          Company for Hong Kong financial 
          reporting and U.S. financial reporting 
          purposes, respectively, and to 
          authorize the Directors to fix 
 3.       the auditors' remuneration.                588,053,284    785,368        42,780             Yes 
                                                      (99.8666%)    (0.1334%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
 Special Resolution 
         To grant a general mandate to 
          the Directors to issue additional 
 4.       shares of the Company.^                    580,202,630   8,636,037       42,765             Yes 
                                                      (98.5334%)    (1.4666%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
 Ordinary Resolution 
         To grant a general mandate to 
          the Directors to repurchase shares 
 5.       of the Company.^                           588,837,389     1,278         42,765             Yes 
                                                      (99.9998%)    (0.0002%) 
        ------------------------------------------  ------------  -----------  --------------  ----------------- 
 

* Percentages rounded to 4 decimal places .

(#) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the Notice of AGM.

Notes:

(1) Except for Dr Karen Jean FERRANTE who had prior overseas commitments and was unable to attend the AGM, all directors of the Company, namely Mr TO Chi Keung, Simon, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Dr Dan ELDAR, Ms Edith SHIH, Mr Lefei SUN, Mr Paul Rutherford CARTER, Mr Graeme Allan JACK and Professor MOK Shu Kam, Tony, attended the AGM, either in person or by means of electronic facilities.

(2) Number of shares entitling the holders to attend and vote on all the resolutions at the AGM: 866,131,390 shares.

(3) Number of shares entitling the holders to attend and abstain from voting in favour as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the !--Listing Rules!..) at the AGM: Nil.

(4) Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.

(5) The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                    +852 2121 8200 
  Annie Cheng, Vice President                        +1 (973) 306 4490 
 
Media Enquiries 
  Americas - Brad Miles,                             +1 (917) 570 7340 (Mobile) / bmiles@soleburystrat.com 
   Solebury Strategic Communications 
  Europe - Ben Atwell / Alex Shaw,                   +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 
   FTI Consulting                                    (Mobile) 
                                                     / HUTCHMED@fticonsulting.com 
  Asia - Zhou Yi, Brunswick                          +852 97 83 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley / Daphne Zhang, 
   Panmure Gordon                                    +44 (20) 7886 2500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMSFAFFEEDSELI

(END) Dow Jones Newswires

May 12, 2023 08:15 ET (12:15 GMT)

1 Year HUTCHMED China Chart

1 Year HUTCHMED China Chart

1 Month HUTCHMED China Chart

1 Month HUTCHMED China Chart

Your Recent History

Delayed Upgrade Clock